Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0ABPLD
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
AbLJ-ConjD
|
|||||
| Synonyms |
AbLJ ConjD
Click to Show/Hide
|
|||||
| Organization |
ADC Therapeutics SA; MedImmune LLC
|
|||||
| Drug Status |
Investigative
|
|||||
| Indication |
In total 1 Indication(s)
Chronic myeloid leukaemia [ICD11:2B33]
Investigative
|
|||||
| Drug-to-Antibody Ratio |
1-2
|
|||||
| Antibody Name |
Anti-CD22 mAb AbLJ
|
|||||
| Antigen Name |
B-cell receptor CD22 (CD22)
|
Antigen Info | ||||
| Payload Name |
Undisclosed
|
|||||
| Linker Name |
AbLJ-ConjD linker
|
|||||
| Conjugate Type |
Random conjugation through nucleophilic lysines.
|
|||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.